Tetryzoline (INN), also known as tetrahydrozoline, is a drug used in some over-the-counter eye drops and nasal sprays. Tetryzoline was patented in 1954, and came into medical use in 1959. It is an alpha-adrenergic receptor agonist that produces local vasoconstriction of conjunctival and nasal mucosal blood vessels, reducing redness and transient congestion; ophthalmic products typically use the hydrochloride salt for aqueous solubility and are commonly formulated at 0.05% w v/v for topical ocular use. Onset of action is within minutes with a duration of effect measured in hours, and formulations are adjusted for pH and tonicity to minimize irritation. Pharmacotechnical considerations include light protection and preservative strategy for multiuse aqueous drops, control of oxidative and hydrolytic degradation pathways, and monitoring for systemic exposure in high-dose or prolonged-use scenarios because of potential cardiovascular effects. Analytical control is typically by HPLC-UV for assay and impurity profiling, with mass spectrometry used for structural identification of related compounds.
Parent: Tetryzoline
Parent: Tetrahydrozoline / Tetryzoline
Parent: Tetryzoline
Typical commercial active pharmaceutical ingredient specifications set assay acceptance in the high nineties percent for the labelled form and control limits for impurities to ensure patient safety and stability; individual known related compounds such as N-oxide derivatives, N-dealkylation products, ring-hydroxylated isomers and desethyl-type impurities are commonly limited to 0.1 to 0.3% w w for each identified impurity, unspecified or unknown impurities are typically limited to not more than 0.05% w w each, and total impurities are commonly limited to 0.5 to 1.0% w w depending on the manufacturer specification. Typical tolerances for residual solvents and inorganic counterions follow standard guidance for pharmaceutical APIs. Routine quality control uses validated chromatographic methods, forced-degradation studies to define degradation pathways, and acceptance criteria based on toxicological thresholds for related compounds.
Tetryzoline is used topically to reduce ocular redness and to relieve nasal mucosal congestion by producing local vasoconstriction; it is indicated for short term symptomatic relief in over-the-counter ophthalmic and some nasal preparations.
A well known ophthalmic brand that contains tetrahydrozoline is Visine; the substance is also marketed under various proprietary names in different regions for eye and nasal formulations.
